Cytosorbents FY2025 EPS Estimate Boosted by HC Wainwright

Cytosorbents Co. (NASDAQ:CTSO) – Investment analysts at HC Wainwright lifted their FY2025 earnings estimates for shares of Cytosorbents in a note issued to investors on Thursday, May 15th. HC Wainwright analyst S. Lee now forecasts that the medical research company will earn ($0.19) per share for the year, up from their prior forecast of ($0.24). HC Wainwright currently has a “Neutral” rating and a $1.00 price target on the stock. The consensus estimate for Cytosorbents’ current full-year earnings is ($0.30) per share. HC Wainwright also issued estimates for Cytosorbents’ Q4 2025 earnings at ($0.06) EPS, FY2026 earnings at ($0.20) EPS, FY2027 earnings at ($0.14) EPS, FY2028 earnings at ($0.10) EPS and FY2029 earnings at ($0.09) EPS.

CTSO has been the subject of a number of other reports. D. Boral Capital reiterated a “buy” rating and issued a $10.00 price objective on shares of Cytosorbents in a research note on Thursday, May 15th. StockNews.com assumed coverage on Cytosorbents in a research report on Wednesday. They issued a “hold” rating for the company.

Cytosorbents Stock Performance

Shares of CTSO opened at $0.84 on Monday. Cytosorbents has a 1 year low of $0.70 and a 1 year high of $1.61. The company has a debt-to-equity ratio of 1.06, a current ratio of 1.97 and a quick ratio of 1.58. The stock’s fifty day moving average price is $0.99 and its two-hundred day moving average price is $0.99. The firm has a market cap of $52.60 million, a PE ratio of -2.33 and a beta of 1.17.

Cytosorbents (NASDAQ:CTSO) last released its earnings results on Wednesday, May 14th. The medical research company reported ($0.06) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.08) by $0.02. The company had revenue of $8.73 million during the quarter, compared to analyst estimates of $9.01 million. Cytosorbents had a negative return on equity of 118.54% and a negative net margin of 49.47%.

Institutional Inflows and Outflows

Institutional investors have recently added to or reduced their stakes in the stock. Goldman Sachs Group Inc. increased its holdings in shares of Cytosorbents by 149.2% during the first quarter. Goldman Sachs Group Inc. now owns 62,662 shares of the medical research company’s stock valued at $63,000 after acquiring an additional 37,519 shares in the last quarter. Avenir Corp boosted its stake in Cytosorbents by 63.1% in the 1st quarter. Avenir Corp now owns 5,044,918 shares of the medical research company’s stock worth $5,045,000 after purchasing an additional 1,950,972 shares in the last quarter. CM Management LLC boosted its stake in Cytosorbents by 36.3% in the 1st quarter. CM Management LLC now owns 954,076 shares of the medical research company’s stock worth $954,000 after purchasing an additional 254,076 shares in the last quarter. Skylands Capital LLC grew its position in Cytosorbents by 7.9% during the 1st quarter. Skylands Capital LLC now owns 3,002,702 shares of the medical research company’s stock valued at $3,003,000 after purchasing an additional 221,080 shares during the last quarter. Finally, Key Client Fiduciary Advisors LLC increased its stake in Cytosorbents by 127.0% during the 1st quarter. Key Client Fiduciary Advisors LLC now owns 78,457 shares of the medical research company’s stock valued at $78,000 after purchasing an additional 43,900 shares in the last quarter. 32.87% of the stock is currently owned by institutional investors.

Cytosorbents Company Profile

Cytosorbents Corporation engages in the research, development, and commercialization of medical devices with its blood purification technology platform incorporating a proprietary adsorbent and porous polymer technology in the United States, Germany, and internationally. Its flagship product is CytoSorb, an extracorporeal cytokine adsorber for adjunctive therapy in the treatment of sepsis, adjunctive therapy in other critical care applications, prevention, and treatment of perioperative complications, and maintaining or enhancing the quality of solid organs harvested from donors for organ transplant; and offers VetResQ, a device for adjunctive therapy in the treatment of sepsis, pancreatitis, and other critical illnesses in animals.